Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Pediatric Drugs

• Publication date

  2024-02-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40272-023-00618-2PMID 38310623
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.

  2023influential reference
• IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis

  2023cited by this paper
• The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis

  2023cited by this paper
• Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

  2022influential reference
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

  2022cited by this paper
• Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming

  2022cited by this paper
• New Insights on Juvenile Psoriatic Arthritis

  2022cited by this paper
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

  2022influential reference
• The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.

  2022influential reference
• Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations

  2022cited by this paper
• Physiotherapy in psoriatic arthritis: A systematic review

  2022cited by this paper
• Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis

  2021cited by this paper
• Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.

  2021cited by this paper
• No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?

  2021cited by this paper
• Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

  2021cited by this paper
• Similarities and Differences Between Juvenile and Adult Spondyloarthropathies

  2021cited by this paper
• Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis

  2021cited by this paper
• Long‐Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow‐Up in the Population‐Based Nordic Juvenile Idiopathic Arthritis Cohort

  2020cited by this paper
• British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update

  2020cited by this paper
• EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

  2020influential reference
• Paradoxical gastrointestinal effects of interleukin-17 blockers

  2020cited by this paper
• Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial

  2020cited by this paper
• Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis

  2020cited by this paper
• Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.

  2020cited by this paper
• 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis

  2019influential reference
• Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

  2019cited by this paper
• Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

  2019cited by this paper
• Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis

  2019cited by this paper
• Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study.

  2019cited by this paper
• Pediatric Psoriatic Arthritis

  2018cited by this paper
• Uveitis and Juvenile Psoriatic Arthritis or Psoriasis.

  2018cited by this paper
• Treating juvenile idiopathic arthritis to target: recommendations of an international task force

  2018cited by this paper
• Identification of genes and signaling pathways associated with the pathogenesis of juvenile spondyloarthritis

  2018cited by this paper
• Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus

  2018cited by this paper
• Obesity and Pediatric Psoriatic Arthritis.

  2017cited by this paper
• Adiposity in Juvenile Psoriatic Arthritis

  2017cited by this paper
• The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes

  2017cited by this paper
• Intermediate monocytes are increased in enthesitis‐related arthritis, a category of juvenile idiopathic arthritis

  2017cited by this paper
• Unraveling the Phenotypic Variability of Juvenile Idiopathic Arthritis across Races or Geographic Areas — Key to Understanding Etiology and Genetic Factors?

  2016cited by this paper
• Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

  2016cited by this paper
• UNderstanding uptake of Immunisations in TravellIng aNd Gypsy communities (UNITING): a qualitative interview study.

  2016cited by this paper
• Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases

  2016cited by this paper
• The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.

  2016cited by this paper
• The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort

  2015cited by this paper
• Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?

  2013cited by this paper
• Cross‐sectional study assessing family members of psoriatic arthritis patients affected by the same disease: differences between Caucasian, South Asian and Afro‐Caribbean populations living in the same geographic region

  2013cited by this paper
• Th17 and Th22 cells in psoriatic arthritis and psoriasis

  2013cited by this paper
• The ClASsification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study

  2012cited by this paper
• Psoriatic arthritis criteria evaluation: CASPAR and Modified CASPAR.

  2011cited by this paper
• Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis

  2011cited by this paper
• Psoriatic juvenile idiopathic arthritis: a tale of two subgroups

  2011cited by this paper
• Juvenile Psoriatic Arthritis: Longterm Outcome and Differentiation from Other Subtypes of Juvenile Idiopathic Arthritis

  2009cited by this paper
• Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis.

  2008cited by this paper
• Subpopulations Within Juvenile Psoriatic Arthritis: A Review of the Literature

  2006cited by this paper
• International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

  2004cited by this paper
• Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients.

  2002cited by this paper
• Evaluation of the ILAR criteria for juvenile idiopathic arthritis.

  2001cited by this paper
• Ef fi cacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study

  year unknowncited by this paper

• Response to the letter for the editor by Sozeri B. et al.

  2026cites this paper
• The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care

  2025cites this paper
• IL-11-mediated macrophage crosstalk drives renal inflammation and fibrosis: A novel therapeutic target in chronic kidney disease.

  2025cites this paper
• Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS)

  2025cites this paper
• Do We Need Distinct Pediatric Classification Criteria for Rheumatic Diseases That Affect Both Children and Adults?

  2024cites this paper